background
end
novel
coronaviru
outbreak
emerg
wuhan
china
caus
organ
subsequ
design
novel
coronaviru
effect
adjunct
glucocorticoid
therapi
manag
patient
sever
lower
respiratori
tract
infect
clear
warrant
investig
method
present
studi
conduct
openlabel
random
control
trial
enrol
subject
chongq
public
health
medic
center
elig
subject
assign
intervent
group
methylprednisolon
via
intraven
inject
dose
mgkgday
day
control
group
glucocorticoid
use
randomli
ratio
subject
group
invit
day
followup
schedul
four
consecut
visit
point
use
clinic
improv
rate
primari
endpoint
secondari
endpoint
includ
time
clinic
improv
intervent
durat
mechan
ventil
durat
hospit
overal
incid
advers
event
well
rate
advers
event
visit
mortal
week
discuss
present
coronaviru
outbreak
third
seriou
global
coronaviru
outbreak
past
two
decad
oral
parenter
glucocorticoid
use
manag
sever
respiratori
symptom
coronavirusinfect
patient
past
howev
remain
definit
evid
literatur
util
system
glucocorticoid
serious
ill
patient
coronavirusrel
sever
respiratori
diseas
inde
type
sever
respiratori
diseas
studi
hope
discov
evid
either
support
oppos
system
therapeut
administr
glucocorticoid
patient
sever
coronaviru
diseas
trial
registr
clinicaltrialsgov
http
wwwchictrorgcnshowprojaspx
coronavirus
rna
virus
may
infect
respiratori
gastrointestin
hepat
central
nervou
system
human
livestock
speci
avian
speci
mani
mammal
wild
anim
human
infect
four
coronavirus
name
usual
lead
mild
selflimit
upper
respiratori
tract
infect
howev
coronavirus
associ
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
may
caus
sever
respiratori
diseas
caus
total
laboratoryconfirm
case
global
past
two
decad
casefat
rate
respect
decemb
novel
coronaviru
novel
coronaviru
emerg
wuhan
hubei
china
clinic
manifest
human
resembl
viral
pneumonia
februari
confirm
case
identifi
china
death
worryingli
confirm
case
coronaviru
diseas
covid
identifi
outsid
china
symptom
infect
nonspecif
includ
fever
cough
myalgia
diarrhea
without
subsequ
develop
dyspnea
sever
case
respiratori
distress
sepsi
septic
shock
report
sar
epidem
therapeut
system
glucocorticoid
wide
administ
patient
infect
sever
acut
respiratori
syndrom
coronaviru
sarscov
subsequ
develop
sever
respiratori
diseas
one
cohort
studi
patient
sar
outbreak
show
use
puls
highdos
methylprednisolon
associ
clinic
improv
patient
sar
anoth
studi
patient
sar
certain
cytokin
level
monocyt
chemoattract
chemokin
interferonginduc
found
reduc
day
glucocorticoid
therapi
howev
previou
retrospect
studi
indic
puls
dose
methylprednisolon
risk
factor
associ
increas
mortal
adjust
odd
ratio
confid
interv
p
addit
retrospect
observ
studi
found
glucocorticoid
therapi
patient
mer
associ
delay
middl
east
respiratori
syndrom
coronaviru
merscov
rna
clearanc
clinic
therapeut
effect
system
glucocorticoid
therapi
patient
current
clear
case
use
system
glucocorticoid
sever
case
warrant
investig
studi
propos
investig
effect
glucocorticoid
therapi
patient
sever
major
object
observ
whether
clinic
necess
therapeut
justif
use
system
glucocorticoid
patient
sever
studi
approv
ethic
committe
chongq
public
health
medic
center
publish
result
studi
medic
journal
conclus
studi
patient
name
appear
publish
articl
access
data
may
obtain
except
research
member
hospit
ethic
committe
studi
conduct
openlabel
random
control
trial
enrol
subject
chongq
public
health
medic
center
studi
protocol
written
devis
accord
standard
protocol
item
recommend
intervent
trial
statement
enrol
intervent
assess
process
describ
figur
obtain
inform
consent
subject
group
invit
day
followup
schedul
four
consecut
visit
point
tabl
blood
urin
sampl
collect
laboratori
test
includ
hematolog
analysi
urinalysi
clinic
chemistri
studi
electrolyt
coagul
test
myocardi
enzym
creactiv
protein
erythrocyt
sediment
rate
procalcitonin
cluster
differenti
cell
count
cell
count
blood
ga
analysi
realtim
revers
transcriptionpolymeras
chain
reaction
rtpcr
item
consid
test
followup
period
list
tabl
advers
event
ae
defin
undesir
outcom
experienc
patient
studi
whether
relat
treatment
glucocorticoid
ae
describ
patient
observ
medic
team
duli
document
seriou
ae
document
detail
investig
notifi
soon
possibl
ae
record
clinic
histori
patient
case
report
form
appropri
medic
terminolog
ae
expediti
resolv
shortterm
glucocorticoid
therapi
usual
caus
mild
side
effect
includ
hypokalemia
glucos
intoler
hypertens
pancreat
cutan
hematolog
immunolog
neuropsycholog
effect
mild
side
effect
revers
upon
discontinu
glucocorticoid
side
effect
associ
longterm
glucocorticoid
use
consid
relev
studi
short
durat
glucocorticoid
prescrib
studi
day
diagnosi
sever
subject
meet
follow
criteria
identif
via
rtpcr
blood
sampl
sputum
sampl
bronchoalveolar
lavag
fluid
nasopharyng
swab
sampl
least
one
follow
condit
respiratori
distress
timesmin
b
oxygen
satur
rest
c
arteri
partial
pressur
oxygen
pao
fraction
inspir
fio
mmhg
mmhg
kpa
respiratori
failur
requir
mechan
ventil
e
septic
shock
develop
f
critic
organ
failur
requir
intens
care
unit
care
subject
includ
studi
satisfi
follow
criteria
age
year
sever
will
give
inform
consent
subject
exclud
studi
satisfi
follow
criteria
allerg
intoler
therapeut
drug
use
studi
pregnant
lactat
women
presenc
sever
system
ill
may
affect
effect
safeti
evalu
studi
microsoft
excel
microsoft
corpor
redmond
wa
usa
use
gener
random
number
subject
consent
elig
confirm
investig
design
random
subject
control
group
intervent
group
ratio
result
record
enter
twice
independ
data
document
case
report
form
immedi
record
excel
databas
miss
valu
verifi
ensur
complet
accuraci
data
much
possibl
data
obvious
abnorm
beyond
upper
limit
normal
laboratori
item
exceed
normal
valu
must
explain
necessari
explan
must
given
physician
dropout
ae
record
time
manner
drug
use
trial
suppli
store
distribut
recycl
accord
relev
regul
data
lock
record
sign
princip
research
sponsor
statist
analyst
data
manag
data
administr
perform
databas
lock
subject
receiv
convent
treatment
accord
guidelin
diagnosi
treatment
version
patient
random
intervent
group
receiv
methylprednisolon
intraven
inject
mgkgday
day
wherea
control
group
receiv
glucocorticoid
therapi
discontinu
regimen
may
occur
particip
substanti
improv
full
cours
treatment
subject
whose
clinic
condit
deterior
cours
treatment
primari
endpoint
chang
sequenti
organ
failur
assess
sofa
day
random
secondari
endpoint
proport
mechan
ventil
use
week
mortal
week
durat
hospit
trial
random
control
trial
two
parallel
group
without
mask
alloc
ratio
random
control
trial
evalu
chang
sofa
score
patient
infect
without
glucocorticoid
therapi
samples
calcul
base
primari
hypothesi
detect
reduct
sofa
score
treatment
nontreat
group
day
glucocorticoid
therapi
pass
softwar
version
ncss
llc
kaysvil
ut
usa
use
power
level
confid
consid
dropout
rate
sampl
size
estim
case
group
random
control
trial
aim
compar
plasma
sarscov
rna
concentr
patient
earli
hydrocortisonetr
group
patient
placebo
group
studi
enrol
total
subject
conduct
end
sar
outbreak
fewer
appropri
patient
avail
recruit
take
account
uncertainti
durat
outbreak
final
sampl
size
may
adjust
unlik
wuhan
chongq
current
rel
small
number
confirm
case
even
smaller
number
sever
case
hope
eventu
recruit
cohort
patient
studi
may
settl
even
smaller
cohort
suitabl
subject
avail
primari
outcom
analysi
present
intervent
group
control
group
use
descript
statist
normal
data
distribut
evalu
kolmogorovsmirnov
test
continu
variabl
describ
mean
valu
standard
deviat
mean
standard
deviat
analyz
use
test
independ
sampl
categor
variabl
analyz
use
chisquar
test
fisher
exact
test
verifi
magnitud
differ
rel
risk
success
estim
intervent
group
control
group
confid
interv
set
valu
p
consid
statist
signific
analys
perform
use
spss
softwar
version
spss
inc
chicago
il
usa
sinc
first
report
decemb
attract
global
attent
owe
similar
sarscov
merscov
caus
fatal
respiratori
diseas
potenti
propag
largescal
human
infect
econom
disrupt
system
glucocorticoid
therapi
could
consid
critic
ill
patient
impact
clinic
outcom
uncertain
avail
data
system
glucocorticoid
therapi
among
coronavirusinfect
patient
mainli
come
studi
patient
sar
mer
whether
glucocorticoid
therapi
definit
benefici
clinic
manag
two
coronaviru
infect
still
debat
glucocorticoid
therapi
use
treatment
sever
sar
earli
anecdot
experi
support
radiolog
find
histolog
featur
critic
ill
patient
sar
similar
patient
acut
respiratori
distress
syndrom
ard
earli
march
china
first
summar
experi
manag
sar
suggest
highdos
glucocorticoid
use
patient
fever
persist
day
radiolog
find
suggest
persist
lung
involv
progress
deterior
three
differ
regimen
use
physician
hong
kong
china
includ
methylprednisolon
mgkg
qid
mgkg
tid
iv
follow
oral
prednisolon
vari
period
dispar
dosag
per
clinic
evalu
hydrocortison
mgkg
qid
mgkg
tid
iv
follow
oral
prednisolon
vari
period
dose
per
clinic
evalu
puls
methylprednisolon
mg
iv
daili
day
follow
mainten
oral
prednisolon
mg
bid
reduc
mg
daili
day
per
clinic
evalu
suggest
glucocorticoid
therapeut
dose
sar
outbreak
high
approxim
treatment
dose
acut
sever
asthma
prescrib
dose
similar
prescrib
organ
reject
transplant
patient
ard
one
studi
compar
puls
glucocorticoid
therapi
methylprednisolon
mgday
nonpuls
glucocorticoid
methylprednisolon
mgday
therapi
find
puls
glucocorticoid
therapi
appear
efficaci
patient
use
puls
glucocorticoid
therapi
lower
oxygen
requir
better
radiograph
outcom
decreas
likelihood
requir
rescu
unfortun
state
studi
random
control
trial
thu
open
possibl
bia
impact
outcom
howev
also
staunch
advoc
use
system
glucocorticoid
patient
one
systemat
review
studi
patient
sarscov
includ
studi
document
glucocorticoid
use
found
studi
inconclus
regard
role
adjunct
use
glucocorticoid
four
studi
demonstr
use
system
glucocorticoid
patient
sar
may
caus
possibl
harm
prospect
random
doubleblind
placebocontrol
trial
compar
earli
hydrocortison
treatment
day
ill
placebo
find
earli
hydrocortison
therapi
associ
higher
subsequ
plasma
viral
load
meanwhil
mani
possibl
complic
glucocorticoid
use
profound
immunosuppress
possibl
emerg
sever
commens
viral
bacteri
infect
invas
fungal
infect
osteonecrosi
psychosi
may
occur
prolong
highdos
glucocorticoid
therapi
glucocorticoid
therapi
also
commonli
use
critic
ill
patient
mer
one
studi
hypoxem
patient
merscov
pneumonia
moder
level
posit
endexpiratori
pressur
initi
glucocorticoid
therapi
patient
differ
mortal
patient
associ
delay
merscov
rna
clearanc
mani
patient
sever
mer
treat
system
highdos
glucocorticoid
intend
revers
progress
respiratori
distress
prevent
lung
chines
medic
journal
vol
wwwcmjorg
fibrosi
howev
approach
proven
success
one
studi
includ
total
patient
symptomat
merscov
found
glucocorticoid
use
associ
increas
mortal
patient
retrospect
cohort
studi
compar
patient
glucocorticoid
group
patient
nonglucocorticoid
group
find
mortal
glucocorticoid
group
similar
nonglucocorticoid
group
glucocorticoid
therapi
associ
delay
merscov
rna
clearanc
adjust
baselin
timevari
confound
factor
infect
occur
patient
develop
mild
symptom
signific
fraction
patient
progress
sever
ard
requir
intens
care
use
glucocorticoid
patient
ard
still
controversi
diverg
result
exist
literatur
highdos
glucocorticoid
one
frequent
use
adjunct
ard
countri
even
though
effect
manag
acut
lung
injuri
yet
clear
one
systemat
review
conduct
analysi
individu
patient
data
random
trial
demonstr
compar
placebo
group
prolong
glucocorticoid
treatment
improv
clinic
outcom
anoth
random
control
trial
show
glucocorticoid
therapi
could
downregul
ardsrel
inflamm
associ
signific
improv
lung
extrapulmonari
organ
dysfunct
well
reduc
mechan
ventil
durat
intens
care
unit
hospit
admiss
durat
studi
meduri
et
al
found
prolong
methylprednisolon
treatment
may
complement
posit
modul
system
inflamm
induc
recoveri
induc
glucocorticoid
resist
coexist
decreas
product
endogen
glucocorticoid
anim
experi
recent
year
provid
evid
use
glucocorticoid
reduc
inflamm
attenu
acut
lung
injuri
reduct
mortal
acut
phase
sever
diseas
howev
studi
suggest
glucocorticoid
therapi
ard
necessari
may
even
aggrav
clinic
pictur
use
hydrocortison
improv
lung
function
sepsisassoci
ard
signific
surviv
benefit
observ
patient
higher
mortal
rate
observ
patient
ard
took
highdos
glucocorticoid
within
day
hospit
admiss
compar
treat
without
highdos
glucocorticoid
exist
studi
ard
assess
effect
glucocorticoid
ident
type
patient
ident
process
diseas
therefor
result
studi
consid
congruent
adjunct
glucocorticoid
therapi
specif
diseas
caus
ard
pneumocysti
jirovecii
pneumonia
shown
reduc
mortal
adult
patient
addit
dosag
glucocorticoid
use
need
factor
highdos
glucocorticoid
therapi
may
increas
ventil
depend
may
possibl
induc
wors
outcom
develop
osteonecrosi
discov
patient
receiv
highdos
glucocorticoid
sar
epidem
number
osteonecrot
lesion
directli
relat
dosag
glucocorticoid
prescrib
addit
highdos
glucocorticoid
use
one
caus
neuropsychiatr
outcom
patient
sar
note
lung
injuri
effect
control
appropri
dose
glucocorticoid
base
diseas
sever
may
benefici
better
outcom
sar
studi
investig
whether
use
middos
shortcours
adjunct
glucocorticoid
therapi
treat
sever
advantag
safe
effect
work
support
chongq
special
research
project
prevent
control
novel
coronaviru
pneumonia
none
